Advanced Biomed Inc. (NasdaqCM: ADVB)
Health Care · Health Care Equipment & Supplies · US
$5.35
+0.75% today · -37.3% 1Y
Advanced Biomed Inc. (NasdaqCM: ADVB) operates in the Health Care Equipment & Supplies industry within the Health Care sector. The company is valued at $8.77M and employs 31 people.
Over the last twelve months the share price has lost 37.3%, trading between 3.61 and 24.23.
Tweenvest scores Advanced Biomed Inc. across four factors: quality 35/100, value 67/100. Its strongest factor is value.
ADVB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.77M
- Revenue (TTM)
- —
- P/E
- 1.26
- EPS
- 4.67
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $24.23
- 52-week low
- $3.61
- Avg volume (3M)
- —
- Shares outstanding
- 1.65M
- Employees
- 31
- Next earnings
- —
About Advanced Biomed Inc.
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
- ISIN
- US00752P2039
- Founded
- 2014
- Listed since
- Mar 6, 2025
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Health Care Equipment & Supplies companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nestmedic S.A.WSE: NST | $9.72M | zł0.69 | 0.00% |
| SpineGuard SAENXTPA: ALSGD | $9.44M | €0.09 | +1.03% |
| Boule Diagnostics AB (publ)OM: BOUL | $9.40M | Skr2.27 | -6.20% |
| Golden Valley Development, IncOTCPK: GVDI | $8.83M | $0.01 | — |
| Izotropic CorporationCNSX: IZO | $8.62M | CA$0.17 | -12.82% |
| Merchavia Holdings and Investments LtdTASE: MRHL | $8.47M | ₪1.24 | +0.41% |
| International Company For Medical Industries S.A.E.CASE: FCMD | $8.44M | EGP7.66 | -0.65% |
| Biomerica, Inc.NasdaqCM: BMRA | $8.42M | $1.86 | +1.08% |
Figures last refreshed Oct 11, 2026.